The core distinction is simple: functional assays like CH50 and AH50 measure what the complement system does, while antigenic assays measure what it contains.
A CH50 test evaluates the entire classical pathway’s ability to lyse antibody-coated cells, demanding that all components from C1 to C9 are present and enzymatically active. An AH50 test does the same for the alternative pathway using rabbit red blood cells. In contrast, antigenic immunoassays—such as ELISA or nephelometry—quantify the exact mass concentration of a specific protein, like C3 or C4, with no information about whether that protein actually works. Functional assays uncover hidden non-functional mutations; antigenic assays pinpoint exactly which component is low or consumed.
The fundamental difference is activity versus mass. CH50/AH50 screen overall pathway integrity by requiring a full cascade of functional proteins. Antigenic assays deliver a precise concentration of a single protein, regardless of whether it’s biologically active, denatured, or fragmented. In diagnostic workflows, functional tests are the initial broad screen; antigenic tests are the targeted follow-up that isolates the culprit protein.
What Each Assay Actively Measures
Understanding the different “languages” these assays speak makes their clinical roles obvious.
The Functional Language: Enzymatic Cascade Integrity
A CH50 (total hemolytic complement) assay quantifies the serum dilution needed to lyse 50% of antibody-sensitized sheep red blood cells. This process mimics immune-complex-driven activation of the classical pathway and requires every component—C1q, C1r, C1s, C4, C2, C3, C5, C6, C7, C8, C9—plus the regulatory C1-inhibitor to be structurally intact and catalytically active. If even one protein is missing or mutated to inactivity, the CH50 result collapses to immeasurable levels.
Similarly, the AH50 assay measures alternative pathway function using unsensitized rabbit erythrocytes, which spontaneously activate the alternative C3 convertase. This test depends on the integrity of C3, C5–C9, Factor B, Factor D, properdin, and regulators like Factor H and I. Both assays report a composite picture of total functional reserve, not a list of component quantities.
The Antigenic Language: Protein Mass Concentration
Antigenic assays—radial immunodiffusion (RID), ELISA, turbidimetry, and nephelometry—use highly specific antibodies to measure the absolute concentration of a single complement protein or activation fragment. They answer “how much” of a given protein is circulating, whether it’s a native component like C3 or C4, or a split product like C3a, C5a, Bb, or the terminal SC5b-9 complex.
Crucially, these methods detect epitopes, not enzyme activity. A denatured, inactive C3 molecule that still carries the target epitope will be counted exactly the same as a fully functional one. Antigenic assays can show normal or even elevated levels of a protein that is biologically inert.
How the Assays Work in Practice
The practical and interpretive implications diverge sharply between the two approaches.
Functional Assays: A Pass/Fail System Test
CH50 and AH50 are inherently global screening tools. They are designed to answer one question: “Is the entire pathway operational?” Because they require the simultaneous function of all pathway components, a low or absent result signals a significant defect somewhere in the cascade—but it does not tell you where.
Setting up these assays demands reagents that mimic physiological activation. The CH50 test requires sheep red blood cells pre-incubated with specific IgM or IgG antibodies (hemolysin) to form EA complexes. The AH50 test exploits the fact that rabbit red blood cells are poor regulators of the human alternative pathway, allowing spontaneous C3b deposition and MAC formation. Both require freshly handled or properly preserved serum to maintain labile proteins like C2 and Factor B.
Antigenic Assays: A Targeted Quantification Tool
When a functional screen comes back abnormal, antigenic immunoassays step in to profile individual components. For example, in a patient with suspected systemic lupus erythematosus, a low CH50 prompts measurements of C4 and C3 via nephelometry. Low C4 with normal C3 patterns classic pathway consumption; low C3 with normal C4 points more to alternative pathway activation.
These assays also excel at measuring activation fragments that are direct proof of ongoing complement turnover. Elevated plasma levels of C4a or Bb indicate classical or alternative pathway activation, respectively, even if total parent protein levels remain normal. Such markers provide a snapshot of disease activity in real time.
The Critical Differences Summarized
Biological Signal
- Functional assays evaluate enzymatic competence across an entire pathway.
- Antigenic assays measure physical presence (mass) of a single molecule.
Component Dependencies
- CH50 requires C1–C9 and C1INH all active; AH50 requires C3, C5–C9, Factor B, D, properdin, H, and I.
- Antigenic assays require only the antibody-binding epitopes on the target protein.
Detection of Hidden Defects
A patient with a non-functional C8 mutant can have completely normal antigenic C8 levels but a near-zero CH50. Functional assays are the only way to catch such mutations, which would otherwise be invisible to quantitative immunoassays.
Type of Result
- CH50/AH50: “percent of normal lysis” or “reciprocal dilution to 50% lysis,” reflecting total pathway capacity.
- Antigenic assays: “mg/dL” or “µg/mL” for a specific protein or fragment, reflecting synthesis, consumption, or catabolism.
Understanding the Trade-offs
Choosing one assay type isn’t about better or worse—it’s about what question you need answered.
The Pitfall of Major Reliance on Functional Assays Alone
A low CH50 tells you a pathway is broken but cannot identify whether C1q, C2, or C9 is the culprit. Functional assays are also exquisitely sensitive to pre-analytical variables—improper sample handling that inactivates heat-labile C2 will falsely depress CH50, mimicking a complement deficiency. Additionally, they provide no information on activation fragments, so you could miss low-level ongoing complement activation that hasn’t yet exhausted total lytic capacity.
The Blind Spots of Relying Only on Antigenic Assays
Normal antigenic levels of C3 and C4 can lull a clinician into missing a profound functional defect. Many hereditary angioedema patients have normal C4 mass but a dysfunctional C1-inhibitor; a functional assay reveals the defect. Antigenic tests also treat fragmented, inactive proteins as “present,” potentially overestimating the available biological reserve.
The Practical Laboratory Constraints
Functional hemolytic assays demand stabilized, calibrated erythrocyte reagents and rigorous temperature control to ensure reproducibility. Antigenic assays, particularly turbidimetric and nephelometric platforms, are more amenable to high-throughput automation but require highly specific monoclonal antibodies and purified protein standards to avoid cross-reactivity with degraded material.
Making the Right Choice for Your Diagnostic Goal
Your clinical question dictates which assay class to deploy—or, more commonly, the order in which to combine them.
- If your primary focus is broad screening for any complement deficiency: Start with a CH50 (and AH50 if alternative pathway disease is suspected). A normal result effectively rules out a homozygous deficiency of any pathway component.
- If your primary focus is pinpointing a specific component deficiency after an abnormal functional screen: Follow up with antigenic nephelometry or ELISA for C2, C3, C4, and others based on the clinical context.
- If your primary focus is monitoring disease activity in an autoimmune disorder like SLE: Use serial antigenic measurements of C3, C4, and activation fragments (C3a, Bb). The falling concentration of native components and rising fragments track immune complex-mediated consumption.
- If your primary focus is detecting non-functional but present protein variants: A combined functional-antigenic approach is mandatory. A normal protein concentration with a collapsed functional assay result directly points to a dysfunctional protein.
A robust complement evaluation isn’t about picking one technique over the other—it’s about sequencing functional screening and antigenic fine-mapping to turn a black-box defect into an actionable molecular diagnosis.
Summary Table:
| Feature | Functional Assays (CH50/AH50) | Antigenic Assays (ELISA, Nephelometry) |
|---|---|---|
| Core Measurement | Biological activity & pathway integrity | Physical mass concentration of a protein/fragment |
| Target Reagents | Intact biological cascade (C1–C9 or Alternative) | Specific epitopes on individual proteins |
| Primary Role | Broad initial screening for overall functional reserve | Targeted follow-up quantification & disease monitoring |
| Detection of Mutated Proteins | Identifies non-functional/mutated active proteins | Cannot distinguish functional from inactive/fragmented proteins |
| Key Sample Sensitivity | High sensitivity to pre-analytical handling/thawing | Moderate sensitivity; measures stable mass/epitopes |
Accelerate Your Complement Assay Development with CamelBio
Whether you are engineering functional hemolytic screens or high-throughput antigenic immunoassays, CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical support, and regulatory consulting. We support your diagnostic journey across every stage—from initial concept to clinical implementation.
Contact our technical team today to optimize your assay reagents and diagnostic workflows!